Neogenomics Coverage Initiated by Analysts at William Blair (NEO)
Stock analysts at William Blair initiated coverage on shares of Neogenomics (NYSE:NEO) in a report issued on Wednesday, TheFlyOnTheWall.com reports. The firm set an “outperform” rating on the stock.
Separately, analysts at Zacks reiterated an “outperform” rating on shares of Neogenomics in a research note to investors on Wednesday, October 23rd. They now have a $7.00 price target on the stock.
Neogenomics (NYSE:NEO) traded up 8.74% during mid-day trading on Wednesday, hitting $3.98. 1,290,174 shares of the company’s stock traded hands. Neogenomics has a 1-year low of $2.05 and a 1-year high of $4.20. The stock has a 50-day moving average of $3.63 and a 200-day moving average of $3.19. The company has a market cap of $194.9 million and a P/E ratio of 203.33.
Neogenomics (NYSE:NEO) last announced its earnings results on Wednesday, October 23rd. The company reported $0.02 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.01 by $0.01. The company had revenue of $16.90 million for the quarter, compared to the consensus estimate of $16.84 million. On average, analysts predict that Neogenomics will post $0.04 earnings per share for the current fiscal year.
NeoGenomics, Inc (NYSE:NEO) operates a network of cancer-focused testing laboratories.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.